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Abstract
The purpose of this project was to conduct a systematic review to assess if using
procalcitonin levels to guide antimicrobial therapy has an impact on the number of days
an adult septic patient is exposed to antimicrobial therapy. Bacterial resistance is a
problem encountered throughout the world. Prolonged exposure is a factor contributing to
widespread bacterial resistance. Sepsis is a condition requiring administration of
antimicrobials that are often continued despite signs of infection. Many biomarkers are
being investigated to facilitate a providers’ decision to discontinue antimicrobial therapy
in the septic patient. Procalcitonin is a biomarker at the forefront of research to
accommodate this decision.
Data tables and a cross-study analysis was conducted to research the primary outcome of
total days a septic patient received antimicrobial therapy in a procalcitonin treatment
group versus traditional empiric antimicrobial therapy. The secondary outcome was the
effect of both groups on mortality rates.
All studies showed a reduction of days a septic patient received antimicrobials. Three of
the five studies concluded there was a reduction of days a septic patient received
antimicrobials. All studies showed a clinically significant decrease of days a septic
received antimicrobials without an increase in mortality. The RCTs included in this
systematic review investigated procalcitonin’s role in small sample sizes making
generalization difficult. Procalcitonin may be used in conjunction with other biomarkers
to guide antimicrobial therapy in the septic patient. Advance Practice Registered Nurses
may utilize this review in providing education and training to peers regarding the use of
procalcitonin in the septic patient.

Table of Contents

Background/Statement of the Problem ...............................................................................1
Literature Review ................................................................................................................3
Theoretical Framework .....................................................................................................16
Method ..............................................................................................................................19
Results ...............................................................................................................................23
Summary and Conclusions................................................................................................29
Recommendations and Implications for Advanced Nursing Practice ..............................34
References .........................................................................................................................37
Appendices.........................................................................................................................44

1
Procalcitonin
Can it Impact the Number of Days a Septic Patient is Exposed to Antimicrobials?
Background/Statement of the Problem
Sepsis is defined as a “life-threatening organ dysfunction caused by a
dysregulated host response to infection” (Marik & Taeb, 2017, p. 943). Early recognition
and treatment of infection is the goal of care. Broad spectrum antimicrobials are
administered until further identifying the source of infection. This method of
administration contributes to the overall length of time a patient is exposed
antimicrobials.
Bacterial resistance to antimicrobials is a proven threat to world health (Lior &
Bjerrum, 2014). Bacteria utilize mechanisms which help them evolve becoming
increasingly resistant to antimicrobials. Evolution is creating multidrug-resistant
organisms (MDROs) that are nearly immune to a number of available antimicrobials.
Multidrug resistant organisms contribute to increased mortality and health care costs. The
Center for Disease Control (CDC) estimates approximately twenty billion dollars are
attributed to the increased cost and nearly 23,000 people die annually from MDROs
(Munita & Arias, 2016).
Research shows overuse or over prescribing contributes to antimicrobial
resistance; in fact, countries prescribing more antimicrobials tend to see higher rates of
resistance (Lior & Bjerrum, 2014). Additional risks associated with overuse of
antimicrobials include the increase of severe disease, length of disease, risk of
complications, mortality rate, health care costs, and risk of adverse effects (Lior &
Bjerrum)
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Reducing prolonged use of antimicrobials is one way to decrease the time a
bacterium is exposed to antimicrobials. Typically, antimicrobials are administered for a
specified time according to the type of infection being treated. During the time of
administration, the infection may potentially be gone but the use of antimicrobial
continues until the predesignated time is reached. Discontinuation of antimicrobials
according to the absence of infection may reduce the time a person is exposed to
antimicrobials.
Procalcitonin is a biomarker being studied and utilized in medical centers as a
guide to initiate, continue, or discontinue antimicrobials. Research exist showing its
effectiveness as a biomarker in distinguishing between viral and bacterial infections. The
question remains as to whether there is a benefit to using procalcitonin to guide
antimicrobial therapy. Can using Procalcitonin levels to guide antimicrobial therapy
impact the number of days an adult septic patient is exposed to antimicrobial therapy?
The purpose of this systematic review was to assess if using procalcitonin levels to guide
antimicrobial therapy has an impact on the number of days an adult septic patient is
exposed to antimicrobial therapy.
Next, the literature review will be discussed.
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Literature Review
Sepsis
The current definition of sepsis is in its third edition and was created in 2016 by
the Surviving Sepsis Campaign (Surviving Sepsis Campaign, n.d.). Sepsis is defined as a
“life-threatening organ dysfunction caused by a dysregulated host response to infection”
(Marik & Taeb, 2017, p. 943). Sepsis and septic shock are connected but distinguishable
by two factors. The additional presence of hyperlactaemia and concurrent use of
vasopressors for treatment defines septic shock (Chausse, Malekele, & Paruk, 2018).
Hyperlactatemia is characterized by a blood level presence of greater than 2mmol/L.
Indiscriminate use of vasopressors does not meet the criteria for septic shock.
Administration of vasopressors after failure of fluid resuscitation characterizes
vasopressor use when diagnosing septic shock (Chausse et al.).
Incidence and cost. The Centers for Disease Control (CDC) investigated causes
of death in the United States of America (USA) from 1999 through 2014. The CDC
found approximately 139,000 deaths were attributed to sepsis in 1999; this number was
increased by 31%, to 182,000 deaths in 2014 (Epstein, Dantes, Magill, & Fiore, 2016).
By 2016, the incidence of death per year caused by sepsis in the USA has risen to over
200,000 people (Moore et al., 2016).
Measuring incidence of sepsis is not consistent and sometimes unreliable (Genga
& Russell, 2017). Statistics related to the incidence of sepsis depend on the data being
researched. Some of the tools utilized to research the incidence of sepsis include
insurance claims, International Classification (ICD) codes, and searching for organ
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dysfunction or infection. Estimates of the incidence of sepsis range from 3 to 10 per
1,000 people annually in industrialized nations (Genga & Russell).
Health care costs for treatment of sepsis in the USA are rising. Annual hospital
admission rates of people with sepsis reach almost one billion people in 2013 (Paoli,
Reynolds, Sinka, Gitlin, & Crouser, 2018). The average daily costs of treatment in 2013
ranged from $1,800 to $3,000 dollars with an estimated annual cost of $24 billion dollars
(Paoli et al.).
Pathophysiology. An infection begins with the immune system recognizing a
pathogen as foreign and responds locally to the site of infection. The immune system is
equipped with pathogen recognition receptors (PRR) allowing them to recognize
pathogens as foreign (Chausse et al., 2018). This ability is possible because pathogens
display pathogen associated molecular patterns (PAMP). Once the PRR recognizes the
PAMP, complexes are formed creating PAMP-PRR complexes (Chausse et al.). The
complexes then release cytokines locally causing the inflammatory response. Sepsis
begins when the innate immunity responds systematically causing a hyperinflammatory
response (Chausse et al.). The hyperinflammatory response consists of cytokine release,
endothelial dysfunction, fibrinolysis, and hypercoagulation.
The cytokines respond in two phases (Chausse et al., 2018). The initial phase
consists of a pro-inflammatory response. The pro-inflammatory response causes
endothelial damage increasing permeability of the vessels leading to increased edema.
Additionally, nitric oxide is released due to endothelial damage. Nitric oxide produces a
vasodilatory effect on vessels further contributing to edema and vascular permeability

5
(Chausse et al.). These cascading events eventually causes a decrease in systemic blood
pressure and hypoperfusion.
The second phase is the anti-inflammatory response, which occurs when the
innate immune system begins to control the pro-inflammatory response. A prolonged proinflammatory response leads to hypoperfusion of vital organs causing damage. The antiinflammatory response acts as a buffer and decreases the number and function of the
circulating monocytes and lymphocytes (Chausse et al., 2018).
Coagulopathies occur because of endothelial damage. Thrombin formation and
fibrinolysis are in flux. Natural anticoagulants become depleted as a result of endothelial
damage (Esmon, 2005). Depletion of protein C, protein S, and thrombomodulin creates a
hypercoagulable state (Chausse et al., 2018).
The results of the pro-inflammatory phase and a hypercoagulable state
consequently create an environment for cellular hypoxia and death (Esmon, 2005).
Cellular hypoxia may result from hypoperfusion of vital organs or emboli created from
the altered coagulation. The damage created in the cells consequently leads to multiorgan
dysfunction further adding to the risk of mortality in the setting of sepsis.
Clinical signs and symptoms. Clinical signs of sepsis include signs of insult or
infection; along, with organ dysfunction. The initial onset of infection usually presents
with classical signs of fever, chills, and an increase or decrease in white blood cells
(Vincent, 2016). Additional signs of infection are dependent of the site of infection. For
example, an infection of the lungs, or pneumonia, will present with signs consistent with
pneumonia. Symptoms may include, but not limited to, fever, shortness of breath,
decreased or absent breadth sounds, and productive cough.
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Organ dysfunction must accompany an insult or infection for the diagnosis of
sepsis (Surviving Sepsis Campaign website, n.d). Infection alone is not enough to
categorize a condition as sepsis, although an infection may progress to sepsis. The
associated organ dysfunction excludes any baseline organ dysfunction a person may have
previous to infection (Singer et al., 2016). Signs of organ dysfunction depend upon which
organ is affected. For example, early signs of renal failure present with oliguria, or low
urine output, and an increase in the serum creatinine.
The SSC endorses the use of the Sequential Organ Failure Assessment (SOFA)
score to predict signs of organ dysfunction. Originally developed by the ESICM in 1994,
the SOFA score is used to quantify signs of organ dysfunction and predict mortality
(Nair, Bhandary, & D’Souza, 2016). From the years 2000 to 2015, a retrospective cohort
analysis of 184,000 adults shows the SOFA score was able to discriminate in hospital
mortality greater than scoring with systemic inflammatory response syndrome (SIRS) and
the quick SOFA score with an area under the receiver operating characteristic curve
(AUROC) of 0.753, confidence interval of 99%, and a probability value of less than
0.001 (Raith, Udy, & Bailey, 2017). Patients are given a score according to their
condition within six categories. The respiratory system is assessed by a score based upon
the patients’ measured partial pressure of oxygen (Pa02), fraction of inspired air (Fi02),
and use of a mechanical ventilator. The hematological system is scored based upon a
patient’s tested platelet value and the neurological system is measured by scoring a
patient according to their presenting Glasgow Coma Scale. Liver function score is based
upon receiving the tested bilirubin and the renal system consists of scoring according to
their tested serum creatinine. Lastly, the cardiovascular system is scored based on the
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patients’ presenting mean arterial pressure (MAP) and/or use of vasoactive medication
(Ferreira, Bota, Bross, Melot, & Vincent, 2001).
Diagnosis. A sepsis diagnosis is considered when a patient presents with signs of
an infection and scores two or greater on the SOFA scale (Singer et al., 2016). The onset
of fever, chills, tachypnea, and increase or decrease in white blood cells may be the first
signs of an infection (Vincent, 2016). The source of infection is not always identified and
may appear from any form of pathogen. Bacteria, parasites, viruses, and trauma are
examples of conditions that may cause sepsis (Polat, Ugan, Cadirci, & Halici, 2017). The
infection then progresses to create a dysregulated immune response eventually leading to
organ dysfunction. The SSC endorses utilizing the SOFA score for assessment of organ
dysfunction. A dysregulated immune response and signs of organ dysfunction categorize
sepsis (Surviving Sepsis Campaign, n.d.) Organ dysfunction must accompany an
infection prior to being diagnosed with sepsis.
Sepsis Treatment
In 2002, The Society of Critical Care Medicine (SCCM) and the European
Society of Intensive Care Medicine (ESICM) convened to develop the Surviving Sepsis
Campaign (SSC). The SSC’s mission is to “reduce mortality and morbidity from Sepsis
and Septic shock worldwide” (Surviving Sepsis Campaign, n.d., para 1). The SSC has
transformed the way health care providers view and treat sepsis and aims to reduce
mortality by making health care providers and the public aware of sepsis. The founders
have campaigned diligently, utilizing research and seminars, to spread the message about
sepsis. The SSC continues to research and provide recommendations for treatment.
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The Surviving Sepsis Campaign first published guidelines for early recognition
and treatment in 2004 (Surviving Sepsis Campaign, n.d.). Guidelines have continued to
evolve through the years. The second edition was accepted by 28 countries in 2008. In
2012, the third edition included the term International. The pinnacle arrived in 2013,
when the United States of America’s (USA) regulatory bodies required treatment of
sepsis according to the published guidelines (Surviving Sepsis Campaign website). The
latest guidelines are in the fourth edition and were published in 2016 with an update in
2018 (Surviving Sepsis Campaign).
The SSC guideline (2018) includes a one-hour bundle. The one-hour bundle
signifies the goal of early recognition and treatment. Identifying the source of sepsis aids
in the treatment. The SSC endorses locating and identifying the cause of sepsis to
adequately provide treatment. Causes of sepsis may arise from noninfectious states, such
as trauma or pancreatitis. Other causes of sepsis may result from bacterial, fungal,
parasitic, or viral infections (Polat et al., 2017). The SSC emphasizes the goal of one hour
to encourage providers to act quickly in identifying and beginning early treatment for
sepsis (Surviving Sepsis Campaign, n.d.). The clock starts from the time sepsis is
identified. The bundle includes obtaining aerobic and anaerobic blood cultures before
administration of antimicrobials, administration of broad spectrum antimicrobials,
measurement of lactate, rapid infusion of 30ml/kg of crystalloid fluids for hypotension or
a lactate greater than 4mmol/L, and application of vasoactive medications for
hypotension during or after fluid resuscitation for maintenance of a MAP of greater than
65mm Hg (Levy, Evans, & Rhodes, 2018). The one-hour bundle goals are illustrated in
Table 1 on the next page.
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Table 1 One-Hour Sepsis Bundle
1

Measure lactate level

2

Obtain blood cultures before administering antimicrobials

3

Administer broad-spectrum antimicrobials

4

Begin rapid administration of 30ml/kg crystalloid for hypotension or lactate less than
4mmol/L

5

Apply vasopressors if hypotensive during or after fluid resuscitation to maintain a mean
arterial pressure greater than 65 mmHg.

(Surviving Sepsis Campaign, n.d.)
The SSC makes additional recommendations within its 2016 guidelines. Empiric
broad spectrum combination therapy with antimicrobials are recommended until the
offending pathogen is discovered and the antimicrobial spectrum can be narrowed
(Society of Critical Care Medicine & European Society of Intensive Care Medicine,
2016). Blood cultures should be obtained prior to administration of antimicrobials but
obtaining cultures should not delay antimicrobial administration. Sepsis-induced
hypotension, or a MAP less than 65mmHg, should first be treated with crystalloids as the
fluid of choice within the first three hours of suspected sepsis. The guidelines endorse
reevaluation of the hemodynamic status continuously and administration of additional
fluids may be warranted based upon the patient’s status (Society of Critical Care
Medicine and European Society of Intensive Care Medicine). Serum lactate levels should
be assessed and used to guide fluid resuscitation efforts. Serum lactate levels >4mmol/L
indicates tissue hypoperfusion in the state of sepsis (Surviving Sepsis Campaign, n.d.).
The guidelines explicitly state a target MAP of 65mmHg and recommend the use of
vasopressors with or after initial fluid administration. Norepinephrine is the vasopressor
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of choice with addition of vasopressin if the patient’s condition warrants a second
vasopressor. The guidelines further suggest assessing cardiac function if the patient’s
hemodynamic status has not improved with the use of vasopressors (Society of Critical
Care Medicine and European Society of Intensive Care Medicine, 2016). The guidelines
also endorse assessing glucose levels frequently and maintaining the glucose level less
than 180mg/dL. Nutritional support is recommended by the guidelines and they advocate
for the use of enteral feedings above all nutritional support options (Society of Critical
Care Medicine and European Society of Intensive Care Medicine).
Antimicrobials
Antimicrobial is a general term for medications with specific actions against
infections (Leekha, Terrell, & Edson, 2011). The term antimicrobials include medications
with antifungal, antibacterial, antiviral, and antiparasitic properties (Leekha et al.). Each
antimicrobial has a specific action to combat different species of bacteria. Broad
spectrum antimicrobials contain activity against multiple types and species of bacteria.
Broad spectrum antimicrobials are administered until a source of infection is discovered
and the bacteria is identified through culture. Antimicrobials are then changed according
to the sensitivity of the bacteria isolated (Roca et al., 2015).
The ‘empiric use’ of antimicrobials involves when clinicians prescribe
antimicrobials without definitive diagnosis of an infection (Michael, Dominey-Howes, &
Labbate, 2014). The patient presents with signs of an infection, but the provider is unable
to identify the source or species of the causative agent. Diagnostic tests can take a few
days to a week to identify the bacterial species. Therefore, empiric use of antimicrobials
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prolong the patient’s overall exposure to antimicrobials and may lead to unwanted
complications or side effects from the medication (Lior & Bjerrum, 2014).
The use of antimicrobials indiscriminately can have an effect on patients. Patients
may suffer from unwanted side effects which may include, but are not limited to, nausea,
vomiting, diarrhea, and headache. Administration of antimicrobials also place patients at
risk for adverse drug reactions (ADRs). Adverse drug reactions account for nearly 6
percent of hospital admissions and occur in approximately 10-15% of hospitalized
patients (Thong & Seng, 2010) and include life threatening skin conditions organ
damage, and organ failure.
Widespread usage of antimicrobials has led to bacterial resistance. Antimicrobials
were once very effective in treating bacterial infections. Widespread use and time have
contributed to certain strains of bacteria evolving and becoming resistant to
antimicrobials (Michael et al., 2014). For example, methicillin-resistant Staphylococcus
aureus (MRSA) is a specific strain of Staphylococcus aureus previously treated routinely
with an antimicrobial named methicillin. Over time, the bacteria have evolved and
became resistant to methicillin. Today, MRSA is considered a MDRO and, “kills more
Americans every year than emphysema, HIV, AIDS, Parkinson’s disease and homicide
combined” (Lior & Bjerrum, 2014, p. 229). The prevalence of MDROs are increasing in
society.
Septic treatment involves the use of antimicrobials. Utilizing a practice of deescalation or discontinuing antimicrobials according to diagnostic criteria may reduce a
person’s exposure, thus reducing a chance for the bacteria to develop resistance. In 2013,
Silva, Atallah, and Salomao conducted a systematic review exploring de-escalation of
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antimicrobials in the septic adult patient. Their initial search results yielded 493 studies,
none of which were randomized control trials (RCTs). The authors concluded current
research was insufficient for evaluating their hypothesis. They were successful in
providing a review for possible future studies into de-escalation practices for reducing
antimicrobial exposure to reduce bacterial resistance (Silva et al.).
Biomarkers
Biomarkers objectively measure a biological response to illness or intervention
(Biron, Ayala, & Lomas-Neira, 2015). Biomarkers may take the form of any
measurement that shows a biological process and can influence or show the effects of
treatment (Strimbu & Tavel, 2010). Biomarkers are being investigated to determine the
best way to predict and treat sepsis. Most investigations surround the use of serum blood
test in identifying biomarkers that may be increased or decreased in the presence of
sepsis. Current investigations include initiating and discontinuing antimicrobial therapy
relative to the blood concentration of the biomarkers. Biomarkers being investigated
include pro-inflammatory cytokines and C-Reactive Protein (CRP), with Procalcitonin
(PCT) being the primary one being investigated (Biron, Ayala, & Lomas-Neira, 2015).
Pro-inflammatory cytokines. The innate immune system includes the human
body’s ability to recognize and attack pathogens through a system of actions (Alberts et
al., 2002). These actions may include an inflammatory response and phagocytosis
(Alberts et al.). Pro-inflammatory cytokines include Tumor Necrosis Factor (TNF),
Interleukin 1b (IL-1b) and Interleukin 6 (IL-6) and they are released to initiate the innate
immune response. Investigations have revealed unreliability in testing serum TNF and
IL- 1b but plasma levels of IL-6 are more consistent and reliable to test as an
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inflammatory marker (Faix, 2013). Studies investigating IL-6 have concluded that IL-6 is
better utilized as a prognostic tool rather than a diagnostic tool. Subsequently, increased
levels of IL-6 are associated with an increase in mortality in people diagnosed with sepsis
(Faix, 2013).
C-reactive protein. C-Reactive Protein is a protein produced in the liver and
upregulated by IL-6 during phases of inflammation (Faix, 2013). C-reactive protein has
been investigated but its specificity to sepsis is low because it indicates inflammation
rather than infection. The specificity of testing CRP is too low to be diagnostic for sepsis
(Biron, Ayala, & Lomas-Neira, 2015).
Procalcitonin
There are two cell types in the human thyroid. The follicular cells produce the
thyroid hormones and the parafollicular cells or C cells produce calcitonin (Cote, Grubbs,
& Hofmann, 2015). Procalcitonin is produced by the C cells of the thyroid and is a
precursor to the hormone Calcitonin (Davies, 2015). During normal health, procalcitonin
is changed into calcitonin in the thyroid and cannot change in any other tissue limiting its
systemic blood concentration. During times of infection, all parenchymal tissue release
procalcitonin causing systemic concentrations to rise above the naturally occurring less
than 0.05ng/L (Davies, 2015). Procalcitonin is down-regulated during viral infection and
upregulated during bacterial infection. Up and down regulation may be useful in guiding
antimicrobial therapy in a septic patient.
In a large prospective study based in 13 U.S. ICU’s (Schuetz et al., 2017), 858
subjects were enrolled in a trial focused on assessing 28-day mortality among sepsis
patients. The authors were investigating if reducing procalcitonin levels by 80% through
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a period of five days impacted the mortality rate among subjects with sepsis. Schuetz et
al. found the 28-day all-cause mortality was two times greater in subjects who did not
show an 80% decrease in Procalcitonin levels at five days from baseline, 20% versus
10% with a probability value of 0.001. The group with a decrease of less than 80%
included 413 patients, 83 succumbed to mortality while 330 patients were alive at 28
days. The group with a decrease of greater than 80% included 233 patients, 24 died and
209 survived 28 days (Schuetz et al.).
A systematic review (Schuetz, Briel, & Mueller, 2013) investigated if measuring
procalcitonin to guide antimicrobial therapy reduced antimicrobial exposure without an
increase in mortality. The review revealed a total of 14 trials of adult patients diagnosed
with respiratory infections. Of the 14, two were in primary care, seven in the emergency
department (ED), and five were conducted in the ICU setting in various countries
throughout the world. The studies occurred between 2004-2011. The authors explained
the results from the trials conducted in the ED and ICU. Subjects from the ED trials
received treatment with antimicrobials according to procalcitonin levels for a mean of 7
days versus 10 days without the use of procalcitonin to guide their antimicrobial therapy.
Subjects from the ICU trials received treatment with antimicrobials according to
procalcitonin levels for a mean of 8 days compared to 12 days without the use of
procalcitonin levels. Of all 14 trials, 118 patients experienced mortality in the
procalcitonin group compared to 134 patients in the control group. Antimicrobial
exposure time was 4 days in the procalcitonin group versus 8 days in the control group.
The authors concluded using procalcitonin to guide antimicrobial therapy reduced the
time of exposure without increasing mortality (Schuetz et al).

15
Sepsis recognition and treatment are evolving. Antimicrobial administration is
paramount in treating infectious causes of sepsis. How long should antimicrobials
continue once the infection has ceased? Finding a diagnostic tool to assist in continuing
or discontinuing antimicrobial administration may reduce exposure to antimicrobials.
Reducing exposure may lead to a decreased prevalence of bacterial resistance. Thus, the
question remains, can using procalcitonin levels to guide antimicrobial therapy impact the
number of days an adult septic patient is exposed to antimicrobial therapy?
Next, the theoretical framework will be discussed.
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Theoretical Framework
Evidence-based practice (EBP) is at the forefront of health care. It has paved the
way to new forms of research within the health care community. Systematic reviews stem
from the desire to synthesize the mounting evidence produced by EBP (Daley, 2016).
Today, systematic reviews are utilized to change practice and formulate guidelines
according to collected evidence (Moher, Liberati, Tezlaff, & Altman, 2009).
In 2009, the Preferred Reporting Items for Systematic Reviews and Meta-analyses
(PRISMA) was established (Daley, 2016). Preferred Reporting Items for Systematic
Reviews and Meta-analyses was created to objectively analyze, write, and assess validity
of research contained within systematic reviews. Preferred Reporting Items for
Systematic Reviews and Meta-analyses also contains a flow diagram enabling the
researcher to identify, organize, structure, and develop the search for evidence included
into a systematic review (Figure 1). The flow diagram takes the author through steps of
identifying relevant articles, screening abstracts for inclusion criteria, assessing full text
articles based on eligibility, and then documenting included and excluded articles utilized
for the systematic review (Liberati et al., 2009).
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Figure 1. PRISMA flow diagram. This figure illustrates the PRISMA flow diagram
(Liberati et al).
Preferred Reporting Items for Systematic Reviews and Meta-analyses includes a
twenty-seven-point checklist, with seven categories, to evaluate research (Figure 2). The
checklist allows for objectively evaluating research to include within a systematic review.
It enables organization of studies and allows the researcher to appraise the research
(Moher et al., 2009). Preferred Reporting Items for Systematic Reviews and Metaanalyses and the PRISMA flow diagram will be utilized to organize and objectively
evaluate research for inclusion of the systematic review.
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Figure 2. The PRISMA checklist. This figure illustrates the PRISMA checklist for
evaluation of research (Liberati et al., 2009).
Next, the method utilized for this systematic review will be discussed.
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Method
Purpose and Research Question
The purpose of the project was to conduct a systematic review investigating the
use of procalcitonin to guide antimicrobial therapy in the setting of sepsis.
The research question: Does using procalcitonin levels to guide antimicrobial
therapy impact the number of days an adult septic patient is exposed to antimicrobial
therapy?
Search Strategy
Online databases were searched using keywords. Search words included sepsis,
procalcitonin, antibiotics and antimicrobials, adults, and intensive care unit, critical care
unit, or ICU. The databases chosen included Google Scholar, Medline, Ovid, and
Pubmed. The PRISMA flow diagram was used to document the search path utilized to
conduct the systematic review.
Inclusion Criteria
Inclusion criteria consisted of RCTs conducted between the years of 2004 to
2019. Adult patients, from ages 18 through 85 years old, were included in the search.
Adults must meet the definition of sepsis as defined by the Surviving Sepsis Campaign: a
“life-threatening organ dysfunction caused by a dysregulated host response to infection”
(Marik & Taeb, 2017, p. 943). Subjects must be receiving antimicrobial treatment in the
intensive care unit (ICU) setting. Procalcitonin levels are required in the treatment group
and must be integrated to guide antimicrobial therapy. All articles are full text and written
in the English language.
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Exclusion Criteria
Exclusion criteria included articles in languages other than English, non-peerreviewed journals, and duplicate studies, pediatric patient population defined as 17 years
or younger, and patients not hospitalized in the ICU. Additionally, studies not defined as
RCTs and RCTs not using a procalcitonin algorithm will be excluded.
Data Collection
Data were collected and analyzed utilizing tables created by the author. Key
information was extracted from RCTs and labeled within the tables. The first table (Table
2 below) identified the following: source of study, purpose of study, study design/setting,
sample, and method utilized. This enabled the author to identify and appraise elements of
RCTs to be included within the systematic review.
Table 2
Data Collection Tool 1
Source

Purpose

Study

Sample

Method

Design/Setting

A second collection tool was used to detail the methods utilized by the researchers
and the results of the study. The table included information pertaining to the specific
procalcitonin algorithm utilized during the study. Next, the total number of days a patient
received antimicrobial therapy was assessed. In Table 3 on the next page, a comparison is
shown between the total number of days subjects received antimicrobial therapy based
upon a procalcitonin algorithm and those in the control group not receiving treatment
based upon a procalcitonin algorithm.
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Table 3
Data Collection Tool 2
Treatment Methods

Intervention
Group

Control Group

Total Days Receiving Antimicrobials

Intervention
Group

Results

Control Group

Appraisal
The Critical Appraisal Programme (CASP) is integral to evaluate RCTs and
provides a systematic framework to assess the integrity and validity of a RCT. The CASP
is comprised of 11 questions, with the first three questions used as a filter before moving
onto the subsequent questions (CASP checklist, 2019). The first three questions decipher
if the trial addresses a clearly focused issue, if patients were assigned to the trial
randomly, and if all patients accounted for in the conclusion. The answer to the first three
questions must be “yes” before moving forward with the CASP. If the first three
questions illicit a “no” response, the validity of the RCT may be in question. The CASP
checklist is an additional tool that was used to evaluate the quality of RCTs (Appendix
C).
Cross Study Analysis
The RCTs were compared with a cross study analysis. Tables were specially
designed by the author to summarize the individual findings of each RCTs. A cross study
analysis was performed by comparing the individual results with each other to further
identify commonalties and/or difference across all studies. Data were analyzed for
decreased utility of antimicrobials based upon using a procalcitonin algorithm. Therefore,
the cross study focused on comparing the treatment group versus a control group,
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whereas, the control group received antimicrobial therapy without the use of a
procalcitonin algorithm.
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Results
Google Scholar, Ovid, Pubmed, and Medline online databases were searched with
the following key words; sepsis, procalcitonin, antibiotics or antimicrobials, adults, and
intensive care unit or critical care unit or ICU. The initial search identified 1,920 articles.
Further screening for duplicate and full text articles yielded 72 results. The articles
remaining were screened for eligibility producing 28 results. Of the 28 results, 5 RCTs
were chosen for inclusion of this systematic review.

1920 Articles Identified

72 Articles remain after duplicates and
non-full text articles removed

72 Articles Screened

28 Full Text articles
assessed for eligibility

44 Articles Excluded

23 Articles
Excluded

5 Studies included in the systematic review

Figure 1. PRISMA flow diagram. This figure illustrates the screening and eligibility of
articles utilized for this systematic review
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Nobre, Harbath, Graf, Rohner, & Pugin conducted a RCT (Appendix A – 1) to
investigate if following procalcitonin levels to guide antimicrobial therapy in suspected
or confirmed sepsis or septic shock impacted the number of days a patient received
antimicrobials (2008). The study included a total of 68 patients after screening for
inclusion and exclusion criteria. The primary outcome measured was the duration of
antimicrobials a patient received. The secondary outcome measured was the 28-day
mortality.
Nobre et al. measured the median antimicrobial duration for the first episode of
infection, total antimicrobial exposure days, and days alive without antimicrobials
(Appendix B – 1) (2008). The median duration of antimicrobial therapy for the first
episode of infection reached a median time of 10 days in the control group and six days
in the procalcitonin group with a statistically significant probability (p) value of 0.003
and a 95% confidence interval. Total antimicrobial exposure, measured as median days,
reached 655 in the control group and 504 in the procalcitonin groups (p = 0.0002). Total
days alive without antimicrobials resulted in 13.6 days and 17.4 days in the control and
procalcitonin group respectively. The secondary outcome studied the 28-day mortality.
The investigators showed a 28-day mortality of six patients in the control group and five
patients in the procalcitonin group or 16.2% in both groups with a probability value of
0.74. Nobre et al. demonstrated a shorter median ICU LOS was reached in the
procalcitonin group, three days vs five days in the control group with clinical significance
(p = 0.03). The critical analysis of Nobre et al. (2008) is illustrated in Appendix C – 1.
The analysis demonstrated that Nobre et al. conducted a sound randomized control trial.
Patients were randomized and blinded to the study.
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Some limitations existed in the study. The trial consisted of a low study
population of 68 patients at a single center. The small sample size cannot effectively be
distributed to represent the general population. The number of dropouts occurring during
the trial was disproportionate between the procalcitonin and control group (8 vs 3, p =
0.197). Difficult to treat organisms were not included in the study for safety reasons and
empiric rules guiding antimicrobial therapy were utilized (Nobre et al.).
The second article (Appendix A – 2) investigated if utilizing procalcitonin levels
to guide antimicrobial therapy in surgical intensive care patients suffering from severe
sepsis decreased the total duration of receiving antimicrobials (Schroeder et al., 2008).
The RCT includes 14 patients after screening for inclusion and exclusion criteria. The
investigators ceased antimicrobials if a patient’s procalcitonin level reached <1ng/ml or a
decrease of 30% by day three from the original sampling. Schroeder et al. found the mean
days of receiving antimicrobials were 6.6 in the procalcitonin group and 8.3 in the control
group (p < 0.001) (Appendix B – 2). Schroeder et al. showed a decrease in antimicrobial
therapy days while utilizing procalcitonin levels to guide therapy. The critical analysis is
illustrated in Appendix C – 2 and it is unclear whether the patients and investigators were
blinded due to insufficient information presented in the study. This study only included a
total of 14 patients and did not investigate the effect of the study on mortality rates.
Annane et al. (Appendix A – 3) investigated the use of procalcitonin levels in
directing antimicrobial treatment in critically ill patients with undifferentiated sepsis
(2013). The multicentered RCT was conducted over a three-year period and involved 53
patients meeting inclusion and exclusion criteria. A total of 53 patients were randomized
to either a procalcitonin based antimicrobial therapy guideline or empiric antimicrobial

26
guidelines. The primary outcome measured was the comparative number of patients
receiving antimicrobials on day five. Secondary outcomes measured included mortality at
day five, at ICU discharge, and at hospital discharge (Annane et al.).
Annane et al. (Appendix B – 3) concluded there were 21 patients receiving
antimicrobial therapy on day five in the control group and 18 patients in the procalcitonin
group (p = 0.24) (2013). There were no observed days in either group that were
antimicrobial free by day five. The mortality rate on day five was equal among the groups
at 10%. The mortality rate by ICU discharge reached 33% in the control group and 23%
in the procalcitonin group. Although the authors concluded there were less patients on
antimicrobials on day five in the procalcitonin group, the findings were not clinically
significant (p = 0.24). The study did demonstrate an overall reduction in mortality rate by
ICU discharge in the procalcitonin group (p = 0.40). The critical analysis of Annane et
al., as shown in Appendix C – 3, demonstrates a well completed randomized control
study.
A noted limitation of the study was physician non-compliance adherence of
drawing procalcitonin levels in the experimental group. Non-compliance in the
procalcitonin group reached 19%. Physician non-compliance was also seen with
discontinuation of antimicrobials based on procalcitonin levels.
The fourth article included in this systematic review is a prospective observational
control study (Appendix A – 4). Bishop et al. investigated if introducing procalcitonin
levels to a teaching hospital would reduce the number of days a septic patient was
exposed to antimicrobials (2014). The primary outcome was considered to be the total
duration of antimicrobial exposure from initiation to discontinuation. Patients were
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compared to historical data of patients with the same demographics, variables, and
severity of illness. The secondary outcome considered was the length of hospital stay and
30-day mortality rates. The study included a total of 100 patients, 50 in each group.
The average duration of antimicrobial therapy (Appendix B – 4), measured in
average days, was 13.3 in the control group compared to 10 in the procalcitonin group (p
= 0.0238) (Bishop et al., 2014). The average length of stay (LOS) in hospital was
measured as 17.8 and 13.5 in the control group versus the procalcitonin group
respectively (P = 0.0299). Length of stay in ICU averaged 12 days in the control group
compared to 8.4 days in the procalcitonin group (P = 0.0767). Furthermore, 30-day
mortality reached two (4%) patients in the control group and one (2%) in the
procalcitonin group (Bishop et al.). The critical appraisal of Bishop et al. is provided in
Appendix C – 4. The investigators executed a well-developed study.
Shehabi et al. conducted a multicenter, prospective, single blind, randomized
control trial investigating the impact of a low serum procalcitonin level cutoff for
antimicrobials in the suspected or confirmed septic patient (Appendix A – 5) (2014). A
total of 394 patients were randomized and included in the trial. The primary outcome
measured was the time of discontinuation of antimicrobial therapy at day 28, death, or
hospital discharge after randomization. Secondary outcomes included ICU and hospital
LOS and 90-day all-cause mortality (Shehabi et al.).
The median days to antimicrobial discontinuation (Appendix B – 5) resulted in 11
and nine (p = 0.58) in the control group compared to the procalcitonin group respectively
(Shehabi et al., 2014). Intensive Care Unit mortality was found to be 8% in the control
group versus 11% in the procalcitonin group (p = 0.28). The 90-day all-cause mortality
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from sepsis was16% and 18% deaths in the control group compared to the procalcitonin
group (p = 0.60). As illustrated in Appendix C - 5, Shehabi et al. was able to conduct a
quality study. A limitation to note is that the study used a low procalcitonin level of
0.1ng/ml as the cutoff to discontinue antimicrobials. Most studies in the literature use a
procalcitonin level of 0.5ng/ml as the achievable level before discontinuing
antimicrobials.
Cross Study Analysis
A cross study analysis of the studies (Appendix D – 1) showed three trials were
conducted in a single center and only two studies included a multicentered approach. All
five studies depicted a reduction of median days patients received antimicrobials (Annane
et al.; Bishop et al.; Nobre et al.; Schroeder et al.; Shehabi et al.). Bishop et al., Nobre et
al., and Schroeder et al. were able to show the reduction with clinical significance (P <
0.5). Four studies did not demonstrate a decrease or increase in mortality rates when
using procalcitonin level to guide antimicrobial therapy in septic patients. Mortality rates
between the intervention and control group were relatively similar, not demonstrating
clinical significance.
Next, the summary and conclusions will be presented.
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Summary and Conclusions
Bacteria have evolved over time becoming more resistant to antimicrobials. Many
factors have been identified as causative of bacterial resistance. Widespread and
prolonged use of antimicrobials is a major contributing factor to bacterial resistance
(Michael et al., 2014). Research reveals that countries that prescribe more antimicrobials
observe higher rates of resistance (Lior & Bjerrum, 2014).
Sepsis is a condition that affects approximately 200,000 people per year in the
USA (Moore et al., 2016). Sepsis treatment requires the use of broad-spectrum
antimicrobials until the causative agent of infection is identified; then, antimicrobial
therapy is adjusted once culture and sensitivity test results are available. The length of
time of antimicrobial therapy is then determined based upon the type and location of
infection guided by principles of the Infectious Diseases Society of America (IDSA)
(Leekha et al., 2011).
Antimicrobial therapy is continued to the end of the specified time recommended
by the IDSA even if a patient is no longer displaying clinical symptoms of an active
infection leading to prolonged antimicrobial exposure. Reducing the exposure time of
antimicrobial therapy may reduce the incidence of bacterial resistance (Lior & Bjerrum,
2014). There are many biomarkers being investigated to aid in determining the time of
antimicrobial discontinuation.
Testing levels of procalcitonin remains at the forefront of promising options to
guide antimicrobial therapy. A 2012 meta-analysis showed a reduction in the length of
antimicrobial therapy in patients suffering from acute respiratory infections without
causing an increase in mortality (Schuetz et al., 2012). The question remains if utilizing
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procalcitonin to guide antimicrobial therapy in patients suffering from sepsis reduces
exposure a patient may experience.
The purpose of this systematic review was to assess if using procalcitonin levels
to guide antimicrobial therapy has an impact on the number of days an adult septic
patient is exposed to antimicrobial therapy. The research question asked if using
procalcitonin levels to guide antimicrobial therapy has an impact on the number of days
an adult septic patient is exposed to antimicrobial therapy. A literature review was first
conducted by the author utilizing inclusion and exclusion criteria. The search strategy
included the use of the following data bases: Google Scholar, Medline, Ovid, and
PUBMED. The PRISMA flow diagram was used to demonstrate the search path and
selection of studies. (Figure 1). Five articles met the inclusion criteria. The primary
outcome investigated was the median duration of antimicrobial exposure experienced in a
patient diagnosed with sepsis receiving care within an ICU. The secondary outcome
measured was the mortality rate associated with antimicrobial therapy among patients
treated traditionally versus use of procalcitonin levels.
Schroeder et al. (2008) was able to demonstrate the most clinically significant
reduction in duration of antimicrobials (P < 0.001). Although the investigators were able
to show highly significant results, it is difficult to assume the same findings may be
applied to a larger study or group because of the small sample size originally studied.
Nobre et al. (2008) demonstrated a reduction in antimicrobial therapy in the
procalcitonin group with statistical significance and a 95% confidence interval (P =
0.003). Total antimicrobial exposure was also significantly witnessed in the procalcitonin
group (655 vs 504, 95% CI, p = 0.0002). The authors observed no difference in 28-day
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mortality when the groups were compared. The mortality rate for both groups were equal.
Nobre et al. successfully demonstrated antimicrobial exposure can be reduced utilizing
procalcitonin levels without increasing 28-day mortality when compared to empiric
antimicrobial therapy.
The study performed by Annane et al. (2013) didn’t demonstrate a clinically
significant difference of duration of antimicrobials (P = 0.52) between the procalcitonin
and control group. The study only randomized a total of 58 patients making
generalization difficult.
Bishop et al. (2014) demonstrated a clinically significant reduction in the length
of antimicrobial therapy without a decrease in 30-day mortality (P = 0.0238). This study
was strictly a single center observational study investigating the introduction of
procalcitonin levels to a university hospital to aid in guiding antimicrobial therapy.
Adherence rates to a specified procalcitonin algorithm were not recorded. Only 28
patients were categorized as having sepsis making it difficult to generalize results.
Shehabi et al., (2014) was not able to show a clinically significant duration of
antimicrobial therapy following procalcitonin levels (P = 0.58). Strengths of the study
include a large randomized population of 394 patients and the investigators witnessed a
high compliance rate with drawing procalcitonin levels and guiding their antimicrobials
according to the level. A limitation to note is that the study used a low procalcitonin level
of 0.1ng/ml which may have contributed to the insignificant change of antimicrobial use
among the groups; when most trials used a cutoff level of 0.5ng/ml. The 90-day all-cause
mortality was nearly identical between the procalcitonin group and control group
(Shehabi et al.).
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The cross study analysis revealed that all studies included showed no change in
mortality when using procalcitonin levels to guide therapy when compared to traditional
administration. Three of the studies reported a decrease in antimicrobial therapy when
discontinuing antimicrobials based upon procalcitonin levels with clinical significance
(Bishop et al.; Nobre et al.; Schroeder et al.). Four studies showed a decrease in the
duration of antimicrobial therapy without an increase in mortality (Annane et al.; Bishop
et al.; Nobre et al.; and Shehabi et al.). One study did not include information regarding
mortality rate (Schroeder et al., 2008).
There were several recognized limitations of the studies reviewed. Four of the
studies contained a small sample size making generalization difficult (Annane et al.;
Bishop et al.; Nobre et al.; Schroeder et al.). Three of the studies were conducted in a
single center further making generalization difficult (Bishop et al.; Nobre et al.;
Schroeder et al.). Specific algorithms were not easily defined in a significant proportion
of the reviewed studies leading to questions regarding the cutoff procalcitonin levels
utilized for discontinuation of antimicrobials. Physician compliance was only discussed
in one of the five studies showing a significant amount of non-compliance. Providers may
feel reluctant with discontinuing antimicrobials based upon an unproven theory.
Limitations exist in this systematic review. The total number of studies included
in this systematic review was low at only five studies. The search for RCTs surrounding
procalcitonin levels guiding antimicrobial therapy in the sepsis patient remains difficult.
Analyzing a few RCTs leads to difficulty in generalizing the population. The RCTs
included in this systematic review included varied demographics that often were not
included in the studies. This also tended to make generalization difficult as there was not
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enough information presented to be confident in guiding clinical decisions based from
these studies.
In conclusion, a clear determination of the use of procalcitonin levels in deciding
to discontinue antimicrobial therapy remains unapparent. Further focused research is
required to make a concise decision to discontinuing antimicrobials based on
procalcitonin levels. The ideal procalcitonin level should be investigated and used
throughout RCTs to better delineate the results of discontinuing antimicrobials.
Randomized control trials should further describe the cause of sepsis to better understand
how procalcitonin levels respond with specific infections. This may aid in understanding
the specific cutoff level of procalcitonin needed to safely discontinue antimicrobials.
Next, the recommendations and implications for advanced nursing practice will
be discussed.
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Recommendations and Implications for Advanced Nursing Practice
Advance Practice Registered Nurses (APRN) are increasingly utilized in the
delivery of healthcare. It is widely accepted there will be physician shortages in the
future. Advanced Practice Registered Nurses can supplement the shortage and have
proven they can effectively manage patients by reducing length of stay, mortality, and
costs associated with patient care (Yeong Woo, Lee, & San Tam, 2017). It is increasingly
fundamental for APRNs to stay current with knowledge, interpret research, and translate
research into practice. Advance Practice Registered Nurses play an active role in the
future of healthcare. They are fundamental in integrating and disseminating their
knowledge through the use of professional organizations to change policies. Advance
Practice Registered Nurses also engage in change at the forefront of healthcare delivery.
Bacterial resistance to antimicrobials continues to be a problem in healthcare. It is
hypothesized that prolonged exposure to antimicrobials contribute to bacterial resistance.
Sepsis is a condition which integrates antimicrobials for treatment and often requires a
prolonged course for treatment. There is no test in existence to indicate when
discontinuation of antimicrobials is indicated. Discontinuation of antimicrobials based
upon procalcitonin levels may reduce the number of days septic patients are exposed to
antimicrobials.
It is the recommendation of this author that more RCTs should be conducted. The
RCTs should include and present clear procalcitonin guidelines utilized for their trial.
Randomized control trials should include a greater sample size to make generalization
possible. It is further recommended that providers adhere to the treatment guidelines set
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by the investigators as evidence shows there is no change in mortality if antimicrobial
therapy duration is reduced.
Procalcitonin may have a role in determining the appropriate time of
discontinuing antimicrobial therapy in a septic patient. Evidence is mounting in the
literature about procalcitonin use and utility, but many more trials should be conducted.
Following procalcitonin levels alone may not be enough to guide the decision to
discontinue antimicrobials. The usefulness of procalcitonin, along with other biomarkers,
may be more reliable when used in conjunction with other biomarkers. Trending more
than one biomarker together increases reliability and may reinforce the idea of
discontinuing antimicrobial therapy. It is imperative that APRNs base their clinical
decisions on the most evidence they obtain and not based upon one test result. At this
time, it is not recommended that procalcitonin levels used alone is diagnostic of infection.
Guidelines and policies are often created by multidisciplinary teams. Nurse
Practitioners (NPs) are increasingly involved in multidisciplinary teams and assists or
leads policy development. Policy development often includes developing guidelines to
provide a standard of care. Nurse Practitioners may utilize this review to help develop
guidelines for procalcitonin’s use. Policies are established in conjunction with guidelines
and serve as a guide to aid providers in making decisions that impact the care of their
patients. Nurse practitioners can further implement the guidelines developed through
providing education and training to personnel impacted by the guidelines.
Advance Practice Registered Nurses may utilize this review in providing
education and training to peers regarding the use of procalcitonin in the septic patient.
This review provides necessary information to adequately decide on procalcitonin’s
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utility in practice. Collaboration with other providers are integral to the NP role. Nurse
Practitioners are situated in a position to be an expert on the topic of procalcitonin’s use
and may provide informal or formal training to their colleagues.
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Appendix A-1
Data Collection Tool 1
Nobre, V., Harbarth, S., Graf, J., Rohner, P., & Pugin, J. (2008). Use of procalcitonin to shorten antibiotic treatment duration in septic
patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine, 177, 498-505:
http://doi.org/10.1164/rccm.200708-1238OC
Purpose
Test whether an algorithm
based on daily evolution of
plasma procalcitonin levels
would help clinicians
shorten the duration of
antimicrobial therapy in
critically ill patients with
suspected or documented
severe sepsis and septic
shock.

Study Design/Setting/Sample
Design: randomized,
controlled, open
interventional trial
Setting: The University
Hospitals of Geneva,
Switzerland
• 1200 bed tertiary care
hospital
Sample: all patients with
suspected severe sepsis or
septic shock admitted to the
ICU from February 2006 to
April 2007 were assessed for
eligibility
• 32 bed mixed
medical/surgical ICU

Method
Randomization: performed using a computer-based random number
generation.
• Allocation made by using opaque, sealed, numbered envelopes
• All patients included had a circulating procalcitonin level
measured at baseline and daily until the 7th day or until
antimicrobials were stopped if before the 7th day.
Inclusion: all patients with suspected severe sepsis or septic shock
admitted to ICU.
• Included patients developing suspected severe sepsis or septic
shock while in the ICU
Exclusion:
• Microbiologically documented infections caused by the
following
o Pseudomonas aeruginosa
o Acinetobacter baumanni
o Listeria spp.
o Legionella pneumophila
o Pneumocystis jiroveci
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•
•
•
•
•
•

282 patients assessed for
eligibility
203 excluded
79 patients randomized
39 assigned to
intervention group
o 31 completed trial
40 assigned to control
group
o 37 completed trial
Total patients completing
trial n - 68

•
•
•
•
•
•

•

o Mycobacterium tuberculosis
Severe infections due to viruses or parasites
Infectious conditions requiring prolong antimicrobial therapy
Antimicrobial therapy begun 48 hours or more before enrollment
Chronic localized infections
Chronic osteomyelitis
Immunocompromised patients:
o CD4 count <200 cells/mm3
o Neutropenic <500 neutrophils/mm3
o Patients on immunosuppressive therapy after solid organ
transplantation
Withholding of life support
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Appendix A-2
Data Collection Tool 1
Schroeder, S., Hochreiter, M., Koehler, T., Schweiger, A.M., Bein, B., Keck, F. S., & von Spiegel, T. (2008). Procalcitonin (PCT)guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a
prospective randomized study. Lagenbecks Archives of Surgery, 394, 221-226. http://dx.doi.org/10.1007/s00423-008-0432-1
Purpose
Investigate the clinical
usefulness of procalcitonin levels
for guiding antimicrobial
treatment in surgical intensive
care patients with severe sepsis

Study Design/Setting/Sample
Design: prospective randomized study
Setting: Intensive care unit of the
Department of Anesthesiology and
Intensive Care Medicine of the
Westkustenklinikum Heide
Sample: patients from October 2006
and April 2007 were eligible for the
study
• 125 patients screened
• 27 patients eligible for study
Intervention group: n=14
• Mean age = 69
• Male gender= 8
• Diagnoses
o Peritonitis: 10
o Pneumonia: 4
Control group: n=13

Method
Patients were screened from October 2006 to April
2007 and randomly assigned to either the intervention
or control group
Inclusion criteria: patients met the criteria by fulfilling
the definition of severe sepsis after abdominal surgery
Exclusion Criteria: patients excluded if did not meet
the respective inclusion criteria, refused informed
consent, or already had received antibiotic treatment
prior to admission to the ICU
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•
•
•

Mean age = 68
Male gender = 7
Diagnoses
o Peritonitis: 9
o Pneumonia: 4
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Appendix A-3
Data Collection Tool 1
Annane, D., Maxime, V., Faller, J. P., Mezher, C., Flech, C., Martel, P., ... Nardi, O. (2013). Procalcitonin levels to guide antibiotic
therapy in adults with non-microbiologically proven appareant severe sepsis: A randomized controlled trial. BMJ Open, 3, 1-7.
http://dx.doi.org/10.1136/bmjopen-2012-002186
Purpose
To investigate whether a
procalcitonin-based algorithm
influenced antibiotic use in
patients with nonmicrobiologically proven
apparent sepsis

Study Design/Setting/Sample
Design: multicenter, randomized
controlled, single-blind trial

Primary outcome: the proportion
of patients on antimicrobials on
day 5 post randomization

Sample: taken from December
2006 to December 2009
• Only 58 patients met eligibility
criteria

Secondary outcomes:
• Death at day 5, ICU
discharge and at hospital
discharge
• Proportion of patients started
on antimicrobials post
randomization

Setting: 2 parallel groups at 8
centers in France in the intensive
care unit

Control Arm: n=28
• Mean age 54
• Female gender 32.1%
Procalcitonin based algorithm:
n=30
• Mean age 59

Method
Patients were eligible if admitted to ICU for <48 hours
and met the following:
• Clinical signs of systemic inflammatory response
syndrome
• Dysfunction of at least 1 organ
• Absence of indisputable infection
• Negative microbiological cultures
Exclusion criteria were:
• Pregnancy
• Burns >15% body surface area (BSA)
• Trauma
• Outpatient or inpatient cardiac arrest
• Post-orthopedic surgery
• Drug related neutropenia
• Withdrawal of life supportive therapies or decision to
withhold them
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•
•
•

•

Duration of antimicrobial
exposure
Sequential Organ Failure
Assessment (SOFA) Score at
day 3 and day 5
Proportion of patients with
infection acquired between
randomization and day 3, day
5, and ICU discharge
Length of Stay (LOS) in ICU
and total hospital stay

•

Female gender 20%

Total randomized patients after
accounting for loss consents
• n = 53

•

Indisputable infection or antimicrobial exposure >48
hours during the time before ICU admission

Randomization:
• 1:1 ratio according to a computer-generated list
• Centralized through a secured website and completed
by an independent statistician
Blinding:
• Control arm: patients, physicians, nurses,
investigators, study coordinators, the statisticians
remained blinded to procalcitonin levels throughout
the study
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Appendix A-4
Data Collection Tool 1
Bishop, B.M., Bon, J. J., Trienski, T. L., Pasquale, T.R., Martin, B.R., & File Jr, T.M. (2014). Effect of introducing procalcitonin on
antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Annals of Pharmocotherapy,
48(5), 577-583. http://dx.doi.org/10.1177/1060028014520957
Purpose
Evaluate the impact of
introducing rapid turnaround
procalcitonin testing at a
large, academic teaching
hospital on antimicrobial use
in critically ill patients with
pneumonia and/or sepsis
Primary outcome: initial
duration of antimicrobial
therapy, defined as number of
days from start to the
intentional discontinuation of
antimicrobial therapy for >24
hours
Secondary outcomes:
• Length of stay (LOS) in
hospital

Study Design/Setting/Sample
Design: prospective, observational, casecontrol study

Method
Eligibility: diagnosis determination was based on
diagnosis-related group codes assigned to patients

Setting: 109 bed tertiary medical/surgical
intensive care unit

Included patients who were 18 years or older and met
the following criteria
• Baseline procalcitonin level measured within 12
hours of admission to the ICU or was in the ICU
with newly suspected infectious process of
pneumonia and/or sepsis
• Received 1 follow-up procalcitonin measurement
at least 48 hours after initial level

Sample: patients in the procalcitonin group
were enrolled from September 2012 to
January 2013
Procalcitonin group: n=50
• Mean age 64
• Male gender 64%
• Diagnosis
o Pneumonia: 35
o Sepsis: 11
o Both: 4
Control group: n=50

Exclusion criteria:
• Neutropenic patients (<500 neutrophils/mL)
• Immunosuppressed patients (i.e., chemotherapy,
radiation therapy, or immunosuppressive
therapy), or chronic steroid use (defined as >3
months of prednisone 7.5mg/d or of a prednisone
equivalent)
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•
•
•
•
•
•

LOS in the ICU
Readmission to the ICU
during the index
admission
300-day readmissions for
any reason
30-day readmission to
hospital for infections
causes
30-day mortality
Relapse of infection:
defined as reinitiation of
antimicrobials for the
initial infection after
antimicrobials were
stopped for >24 hours

•
•
•

Mean age 61
Male gender 64%
Diagnosis
o Pneumonia: 39
o Sepsis: 8
o Both: 3

•
•

•
•

Patients with >24 hours of antimicrobial therapy
prior to initial procalcitonin measurement
Patients diagnosed with infections requiring longterm antimicrobial therapy (i.e., endocarditis,
osteomyelitis, anterior mediastinitis post-cardiac
surgery, hepatic or cerebral abscess, chronic
prostatitis, or infection with mycobacterium
tuberculosis, pneumocystis jirovecii, or
toxoplasma gondii)
Patients who had “Do not Rescusitate” orders
Patients who had a poor chance of survival based
upon Acute Physiology and Chronic Health
Evaluation II (APACHE II) score >25

Procalcitonin algorithm was included in the
procalcitonin level order
Control: The procalcitonin group was matched to
historical controls admitted to same institution from
January 2011 to 2011 on primary diagnosis, gender,
age, APACHE II criteria and score
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Appendix A-5
Data Collection Tool 1
Shehabi, Y., Sterba, M., Garrett, P. M., Rachakonda, K. S., Stephens, D., Harrigan, P., ... Fraser, J. F. (2014). Procalcitonin algorithm
in critically ill adults with undifferentiated infection or suspected sepsis: a randomized controlled trial. American Journal of
Respiratory and Critical Care Medicine, 190(10), 1102-1110. http://dx.doi.org/10.1164/rccm.201408-1483OC
Purpose
To investigate the effect of a
low procalcitonin cut-off on
antimicrobial prescriptions
Primary outcome: the
cumulative number of
antimicrobial treatment days
at day 28

Study Design/Setting/Sample
Design: prospective, singleblind, randomized,
controlled, investigatorinitiated trial
Setting: 11 Australian
intensive care units
• Conducted in Australia
between March 2011 and
December 2012
Sample: 1567 patients
screened
• 1167 excluded
• 400 total patients
randomized
• 6 withdrawn
Intervention group: n=196

Method
Randomization: patients were variable block randomized 1:1
through a secured central study website.
• Randomized to either a procalcitonin group or clinician-guided
group
• Stratified according to the presence of septic shock (defined by
receipt of inotropes and/or any vasopressors within the previous
24 hours
Eligibility criteria: 18 years and older
• Admitted to the ICU within the precious 72 hours receiving
parenteral and/or enteral antimicrobials for suspected bacterial
infection
• With two or more systemic inflammatory response syndrome
criteria
• Expected to remain in the ICU for longer than 24 hours
Exclusion criteria:
• Patients receiving antimicrobials for surgical prophylaxis
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•
•
•

Mean age: 63
Male gender: n=93
Diagnoses
o Sepsis: n=103
o Severe
sepsis/shock:
n=93

Control group: n=198
• Mean age: 65
• Male gender: n=119
• Diagnoses
o Sepsis: n=105
o Severe
sepsis/shock:
n=93

•
•
•
•
•
•
•
•

Proven bacterial infection requiring more >3 weeks
antimicrobial therapy
Isolated systemic fungal or systemic viral infection in absence
of bacterial infection
Neutropenia with a count <1,000 cells/uL
Patients receiving immunosuppressive therapy
Cardiac surgery, trauma, or heat stroke within 48 hours
Medullary thyroid or small cell lung cancer
Not expected to survive to hospital discharge
Known pregnancy
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Appendix B-1
Data Collection Tool 2
Nobre, V., Harbarth, S., Graf, J., Rohner, P., & Pugin, J. (2008). Use of procalcitonin to shorten antibiotic treatment duration in septic
patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine, 177, 498-505:
http://doi.org/10.1164/rccm.200708-1238OC
Treatment Methods
Intervention Group

Control Group

Procalcitonin Levels
• Measure at baseline and daily until the
7th day of follow up
• Then measured every 5 days even if
the patient was transferred out of the
ICU
Antimicrobial Treatment:
• All patients received initial
antimicrobial therapy based on
organization guidelines, susceptibility,
and treating physician who was blinded
to the study
• Broad spectrum antimicrobials were
given to patients with suspected severe
sepsis or septic shock according to the

Total Days Receiving
Results
Antimicrobials
Intervention
Control Group
Group
Duration of
Duration of
Clinical Demographics:
antimicrobial antimicrobial
therapy,
therapy,
Community Acquired Pneumonia
median day
median day
Control group
Intervention group
and (range)
and (range)
• 6 (3-34)
• 10 (3-33)
65%
71%
• P = 0.003 • P = 0.003
P = 0.35

Sepsis of Pulmonary Origin
Control group

Intervention group

67%

64%
P = 0.93
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suspected source of infection and
microbiological cultures when
available, then narrowed according to
susceptibility testing

Septic Shock
Control group

Intervention group

42%

43.6%
P = 0.89

28 Day Mortality
Control group

Intervention group

20%

20.5%
P = 0.82

Procalcitonin Levels
• Measured the
same as above
but stopped
when
antimicrobial
therapy was
discontinued
according to
procalcitonin
levels
• Procalcitonin
levels provided

Procalcitonin
Levels
• Procalcitonin
levels kept in
the laboratory
and not
communicated
to treating
physicians
Study
Investigators:

Median PCT levels on admission
Control group

Intervention group

5.9µg/L

8.4µg/L
P = 0.75
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to team within 3
hours of drawing
Investigators used
predefined stopping
rules based on
circulating
procalcitonin levels:
• Patients with
baseline
procalcitonin
levels greater
than or equal to
1 µg/L were reevaluated day 5
• Discontinuation
of antimicrobials
was encouraged
for procalcitonin
levels that
dropped >90%
from baseline
peak level or a
value below 0.25
µg/L
• Patients with
baseline
procalcitonin
levels less than 1

•

Did not
interfere with
duration of
antimicrobial
therapy
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µg/L at baseline
were reevaluated on day
3 and
antimicrobials
were
discontinued if
levels were less
than 0.1 µg/L
Final decision to
continue
antimicrobial
therapy was left to
the discretion of the
physician and
defined as
“overruled by
physician”
Positive blood
cultures:
• Were ensured to
receive at least 5
days of
antimicrobial
therapy
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Appendix B-2
Data Collection Tool 2
Schroeder, S., Hochreiter, M., Koehler, T., Schweiger, A.M., Bein, B., Keck, F. S., & von Spiegel, T. (2008). Procalcitonin (PCT)guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a
prospective randomized study. Lagenbecks Archives of Surgery, 394, 221-226. http://dx.doi.org/10.1007/s00423-008-0432-1
Treatment Methods
Intervention
Control Group
Group
Daily standard labs included CReactive Protein
Procalcitonin
Antimicrobial
measured
therapy
discontinuation
Antimicrobial
occurred
therapy
according to
discontinuation
clinical signs and
occurred once the empiric rules
following criteria
was met:
• Clinical signs
and symptoms
of sepsis
improved

Total Days Receiving
Antimicrobials
Intervention
Control Group
Group
Duration of
Duration of
antimicrobial
antimicrobial
therapy, mean
therapy, mean
days/standard
days/standard
deviation
deviation
• 6.6 ± 1.1
• 8.3 ± 0.7
• P = 0.001
• P = 0.001

Results

Diagnoses:
Peritonitis
Control group

Intervention group

9

10
Pneumonia

4

4

Underlying pathology for peritonitis with percentage
of population:
Colonic-sigmoid perforation
Anastomotic leakage
Transmigration peritonitis

28%
21%
15%
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•

•

Procalcitonin
levels
decreased to
1ng/L or a
drop of 2535% from the
initial
procalcitonin
levels over
three
consecutive
days
The physician
was free to
continue
antimicrobials
based upon
clinical
judgement

Small bowel perforation
Gastric perforation
Gallbladder perforation
Tubo-ovarian abscess

11%
15%
5%
5%

ICU Days: mean/standard deviation
Control group

Intervention group

16.7 ± 5.6

16.4 ± 8.3
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Appendix B-3
Collection Tool 2
Annane, D., Maxime, V., Faller, J. P., Mezher, C., Flech, C., Martel, P., ... Nardi, O. (2013). Procalcitonin levels to guide antibiotiv
therapy in adults with non-microbiologically proven apparent severe sepsis: A randomized controlled trial. BMJ Open, 3, 1-7.
http://dx.doi.org/10.1136/bmjopen-2012-002186
Treatment Methods

Total Days Receiving
Antimicrobials

Intervention Group

Control
Group

Initiation and
discontinuation of
antimicrobials was
guided by a
procalcitonin based
algorithm.

Decision to
Number of patients on
start or stop
antimicrobial therapy at
antimicrobials
Day 5 P = 0.24
was at the
Survivors
Survivors
discretion of
only
only
the physician • 18 (67%) • 21
without
(86%)
knowing the
procalcitonin
level.

Procalcitonin levels
drawn at the following
intervals:
• 6 hours
• Day 3
• Day 5

Intervention
Group

Results

Control
Group
Day 5
Intervention Group
3/31 (10%)

Control
Group
3/31 (10%)

ICU discharge
7/31 (23%)

10/30 (33%)

Hospital Discharge
10/30 (33%)

ICU
Intervention
Group
22 (8-42)

Control Group
23 (10-60)
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Antimicrobial therapy
recommendations based
on procalcitonin levels:
• <0.25 µg/L:
antimicrobials
halted and not
recommended to be
started
• ³ 0.25 µg/L <0.5µg/L:
antimicrobials were
strongly discouraged
• ³ 0.5 µg/L <5 µg/L:
antimicrobials
recommended
• ³ 5µg/L:
antimicrobials
strongly
recommended
• Investigators were
asked not to overrule the algorithm
every day up to Day
5

Hospital
27 (9-49)
33 (11-69)
7/31 (23%)
Mortality:
Length of stay (days)
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Appendix B-4
Data Collection Tool 2
Bishop, B.M., Bon, J. J., Trienski, T. L., Pasquale, T.R., Martin, B.R., & File Jr, T.M. (2014). Effect of introducing procalcitonin on
antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Annals of Pharmocotherapy,
48(5), 577-583. http://dx.doi.org/10.1177/1060028014520957
Treatment Methods

Total Days Receiving
Antimicrobials

Intervention Group

Intervention
Group

This was a prospective, observational
study. Procalcitonin levels became
available for physician order. An
algorithm was included with
recommendations for antimicrobial
therapy

Total days of antimicrobial
therapy P = 0.0238

Procalcitonin levels:
• Baseline procalcitonin level
measured within 12 hours of
admission to the ICU or was in the
ICU with newly suspected infectious
process of pneumonia and/or sepsis

10 (±4.9)

Results

Control
Group

13.3 (±7.2)

Length of Stay in hospital P = 0.0299
Intervention
Group
13.5 (±6.6)

Control Group
17.8 (±11)

Length of stay in ICU P = 0.0767
8.4 (±5.8)

12 (± 9.7)
30 Day mortality P = 0.5

1 (2%)

2 (4%)
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•

Received 1 follow-up procalcitonin
measurement at least 48 hours after
initial level

Antimicrobial recommendations based
on procalcitonin algorithm for lower
respiratory tract infections
Group A: Initial Procalcitonin Levels
• <0.1 µg/L: antimicrobial
initialization strongly discouraged
• 0.1 µg/L – 0.24 µg/L: initiation
discouraged
• ³ 0.25 µg/L – 0.5 µg/L: Initiation
encouraged
o Repeat procalcitonin every 48
hours to consider early
antimicrobial discontinuation
• >0.5 µg/L: Initiation strongly
encouraged
o Repeat procalcitonin level
every 48 hours to consider
early antimicrobial
discontinuation
Group B: Follow up procalcitonin levels
• <0.1 µg/L or drop by >90%:
discontinuation of antimicrobials
strongly encouraged
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•
•
•

0.1 µg/L – 0.24 µg/L or drop by
>80%: discontinuation of
antimicrobials encouraged
³ 0.25 µg/L – 0.5 µg/L:
discontinuation of antimicrobials
discouraged
>0.5 µg/L: discontinuation of
antimicrobials strongly discouraged

Sepsis procalcitonin algorithm
Group A: initial procalcitonin levels
• <0.25 µg/L: antimicrobial initiation
strongly discouraged
• 0.25 µg/L – 0.49 µg/L: antimicrobial
initiation discouraged
• ³ 0.5 µg/L – 1.0 µg/L: antimicrobial
initiation encouraged
• > 1.0 µg/L: antimicrobial initiation
strongly encouraged
Group B: follow up procalcitonin levels
• <0.25 µg/L: antimicrobial
discontinuation strongly encouraged
• 0.25 µg/L – 0.49 µg/L or drop by
80%: antimicrobial discontinuation
encouraged
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•
•

³ 0.5 µg/L and drop by 80%:
antimicrobial discontinuation
discouraged
³ 0.5 µg/L and rising or not
decreasing: antimicrobial
discontinuation strongly discouraged
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Appendix B-5
Data Collection Tool 2
Shehabi, Y., Sterba, M., Garrett, P. M., Rachakonda, K. S., Stephens, D., Harrigan, P., ... Fraser, J. F. (2014). Procalcitonin algorithm
in critically ill adults with undifferentiated infection or suspected sepsis: a randomized controlled trial. American Journal of
Respiratory and Critical Care Medicine, 190(10), 1102-1110. http://dx.doi.org/10.1164/rccm.201408-1483OC
Treatment Methods
Intervention Group Control Group
Procalcitonin levels were measured on
all patients at randomization and daily
thereafter until ICU discharge or up to 7
days, whichever came first.
Procalcitonin
Procalcitonin
levels were made
levels were faxed
available to
directly to the
treating physician. Clinical
Informatics and
Procalcitonin
Data Management
algorithm: treating Unit and not made
physicians had the available to
option to overrule treating
the algorithm as
physicians.
clinically
indicated.

Total Days Receiving Antimicrobials
Intervention
Control Group
Group
Median days of time to antimicrobial
discontinuation P = 0.58
9 (6-20)

11 (6-22)

Results
ICU Length of Stay (Median) P = 0.87
Intervention
Group
6 (3-9.5)

Control Group
6 (4-10)

Hospital Length of Stay (Median) P = 0.19
15 (9-29)

17 (10-32)
ICU Mortality

21 (11%)

15 (8%)

Hospital Mortality
30 (16%)

26 (13%)

90 Day all-cause Mortality
35 (18%)

31 (16%)
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Discontinue
antimicrobials if:
• Initial or
subsequent
procalcitonin
level is
negative or <
0.10 ng/ml
• Initial or any
subsequent
procalcitonin
level is
borderline 0.10
– 0.25 ng/ml
and infection is
unlikely
• Subsequent
procalcitonin
level declined
³ 90% from
baseline
• Assess
appropriateness
and source
control of
antimicrobials
if procalcitonin
levels at 48

68

hours >70% of
baseline value
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Appendix C-1
Critical Appraisal Skills Program
Nobre, V., Harbarth, S., Graf, J., Rohner, P., & Pugin, J. (2008). Use of procalcitonin to shorten antibiotic treatment duration in septic
patients: a randomized trial. American Journal of Respiratory and Critical Care Medicine, 177, 498-505:
http://doi.org/10.1164/rccm.200708-1238OC
1
2
3
4
5
6
7
8

Section A: Are the results of the trial valid?
Did the trial address a clearly focused issue?
Yes
Can’t Tell
No
Was the assignment of patients to treatments
Yes
Can’t Tell
No
randomized
Were all of the patients who entered the trial
Yes
Can’t Tell
No
properly accounted for at its conclusion
Is it worth continuing?
Were patients, health workers, and study
Yes
Can’t Tell
No
personnel “blind” to treatment
Were the groups similar at the start of the
Yes
Can’t Tell
No
trial
Aside from the experimental intervention,
Yes
Can’t Tell
No
were the groups treated equally?
Section B: What are the results?
How large was the treatment effect?
The median days receiving antimicrobial therapy: control group – 9.5/
Intervention group – 6 (p = 0.15)
How precise was the estimate of the
Total antimicrobial exposure days were lower in the procalcitonin group
treatment effect?
compared with the control group {504 vs 655 days, incidence rate ratio (IRR)
1.1; 95% Confidence Interval (CI), P = 0.07}
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9

Can the results be applied to the local
population, or in your context?
10 Were all clinically important outcomes
considered?
11 Are the benefits worth the harms and costs?

Yes

Can’t Tell

No

Yes

Can’t Tell

No

Yes

Can’t Tell

No
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Appendix C-2
Critical Appraisal Skills Program
Schroeder, S., Hochreiter, M., Koehler, T., Schweiger, A.M., Bein, B., Keck, F. S., & von Spiegel, T. (2008). Procalcitonin (PCT)guided algorithm reduces length of antibiotic treatment in surgical intensive care patients with severe sepsis: results of a
prospective randomized study. Lagenbecks Archives of Surgery, 394, 221-226. http://dx.doi.org/10.1007/s00423-008-0432-1
1
2
3
4
5
6
7
8
9

Section A: Are the results of the trial valid?
Did the trial address a clearly focused issue?
Yes
Can’t Tell
No
Was the assignment of patients to treatments
Yes
Can’t Tell
No
randomized
Were all of the patients who entered the trial
Yes
Can’t Tell
No
properly accounted for at its conclusion
Is it worth continuing?
Were patients, health workers, and study
Yes
Can’t Tell
No
personnel “blind” to treatment
Were the groups similar at the start of the
Yes
Can’t Tell
No
trial
Aside from the experimental intervention,
Yes
Can’t Tell
No
were the groups treated equally?
Section B: What are the results?
How large was the treatment effect?
The mean days of receiving antimicrobials were 6.6 in the procalcitonin guided
group vs 8.3 in the control group (p = <0.001)
How precise was the estimate of the
Statistical analysis conducted using the Mann-Whitney U test and differences
treatment effect?
were analyzed by using the chi-square test
Can the results be applied to the local
Yes
Can’t Tell
No
population, or in your context?
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10 Were all clinically important outcomes
considered?
11 Are the benefits worth the harms and costs?

Yes

Can’t Tell

No

Yes

Can’t Tell

No
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Appendix C-3
Critical Appraisal Skills Program
Annane, D., Maxime, V., Faller, J. P., Mezher, C., Flech, C., Martel, P., ... Nardi, O. (2013). Procalcitonin levels to guide antibiotiv
therapy in adults with non-microbiologically proven apparent severe sepsis: A randomized controlled trial. BMJ Open, 3, 1-7.
http://dx.doi.org/10.1136/bmjopen-2012-002186
1
2
3
4
5
6
7
8

Section A: Are the results of the trial valid?
Did the trial address a clearly focused issue?
Yes
Can’t Tell
No
Was the assignment of patients to treatments
Yes
Can’t Tell
No
randomized
Were all of the patients who entered the trial
Yes
Can’t Tell
No
properly accounted for at its conclusion
Is it worth continuing?
Were patients, health workers, and study
Yes
Can’t Tell
No
personnel “blind” to treatment
Were the groups similar at the start of the
Yes
Can’t Tell
No
trial
Aside from the experimental intervention,
Yes
Can’t Tell
No
were the groups treated equally?
Section B: What are the results?
How large was the treatment effect?
At Day 5 post-randomization, 67% of the intervention and 81% of the control
group was receiving antimicrobials
How precise was the estimate of the
At Day 5 post-randomization, the intervention group 18/27 vs 21/26 patients in
treatment effect?
the control group receiving antimicrobials (95% CI, relative risk (RR) = 0.83, p
= 0.24)
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9

Can the results be applied to the local
population, or in your context?
10 Were all clinically important outcomes
considered?
11 Are the benefits worth the harms and costs?

Yes

Can’t Tell

No

Yes

Can’t Tell

No

Yes

Can’t Tell

No
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Appendix C-4
Critical Appraisal Skills Program
Bishop, B.M., Bon, J. J., Trienski, T. L., Pasquale, T.R., Martin, B.R., & File Jr, T.M. (2014). Effect of introducing procalcitonin on
antimicrobial therapy duration in patients with sepsis and/or pneumonia in the intensive care unit. Annals of Pharmocotherapy,
48(5), 577-583. http://dx.doi.org/10.1177/1060028014520957
1
2
3
4
5
6
7
8

Section A: Are the results of the trial valid?
Did the trial address a clearly focused issue?
Yes
Can’t Tell
No
Was the assignment of patients to treatments
Yes
Can’t Tell
No
randomized
Were all of the patients who entered the trial
Yes
Can’t Tell
No
properly accounted for at its conclusion
Is it worth continuing?
Were patients, health workers, and study
Yes
Can’t Tell
No
personnel “blind” to treatment
Were the groups similar at the start of the
Yes
Can’t Tell
No
trial
Aside from the experimental intervention,
Yes
Can’t Tell
No
were the groups treated equally?
Section B: What are the results?
How large was the treatment effect?
The average days of receiving antimicrobial therapy were 10 in the
procalcitonin group vs 13.3 (95% CI = 0.9-5.76; p = 0.0238)
How precise was the estimate of the
The Wilcoxon-Mann Whitney test was used to evaluate the difference in the
treatment effect?
duration of antimicrobial therapy. The Anderson-Darling test was used to test
for data normality.
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Can the results be applied to the local
population, or in your context?
10 Were all clinically important outcomes
considered?
11 Are the benefits worth the harms and costs?

Yes

Can’t Tell

No

Yes

Can’t Tell

No

Yes

Can’t Tell

No
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Appendix C-5
Critical Appraisal Skills Program
Shehabi, Y., Sterba, M., Garrett, P. M., Rachakonda, K. S., Stephens, D., Harrigan, P., ... Fraser, J. F. (2014). Procalcitonin algorithm
in critically ill adults with undifferentiated infection or suspected sepsis: a randomized controlled trial. American Journal of
Respiratory and Critical Care Medicine, 190(10), 1102-1110. http://dx.doi.org/10.1164/rccm.201408-1483OC
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Section A: Are the results of the trial valid?
Did the trial address a clearly focused issue?
Yes
Can’t Tell
No
Was the assignment of patients to treatments
Yes
Can’t Tell
No
randomized
Were all of the patients who entered the trial
Yes
Can’t Tell
No
properly accounted for at its conclusion
Is it worth continuing?
Were patients, health workers, and study
Yes
Can’t Tell
No
personnel “blind” to treatment
Were the groups similar at the start of the
Yes
Can’t Tell
No
trial
Aside from the experimental intervention,
Yes
Can’t Tell
No
were the groups treated equally?
Section B: What are the results?
How large was the treatment effect?
Primary outcome of median days to antimicrobial cessation at 28 days.
Intervention group 9 days vs 11 days in the control group (p = 0.58)
How precise was the estimate of the
The Cox proportional hazard regression model was used to account for baseline
treatment effect?
imbalances, time to antimicrobial cessation, and was adjusted for age, sex, and
baseline procalcitonin levels (1.44, p = 0.20)
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Can the results be applied to the local
population, or in your context?
10 Were all clinically important outcomes
considered?
11 Are the benefits worth the harms and costs?

Yes

Can’t Tell

No

Yes

Can’t Tell

No

Yes

Can’t Tell

No
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Appendix D – 1
Cross Study Analysis
Author/Year

(Nobre, Harbarth, Graf,
Rohner, & Pugin, 2008)

(Schroeder et al., 2008)

Single Vs Multicenter

Single

Single

(Annane et al., 2013)
(Bishop et al., 2014)
(Shehabi et al., 2014)

Multicenter

Duration of Antimicrobials
(median days)
Intervention
Control
Group
Group
N-6
N - 10
P = 0.003
N – 6.6
N – 8.3
P < 0.001
N–5
N–5
P = 0.52
N – 10
N – 13.3
P = 0.0238

Single
Multicenter

N–9

N – 11
P = 0.58

Mortality
Intervention
Control Group
Group
28 – Day Mortality
N–5
N – 6 (16.2%)
(16.1%)
P = 0.74
Not Reported
Mortality at ICU Discharge
N – 7 (23%)
N – 10 (33%)
P = 0.40
30 Day Mortality
N – 1 (2%)
N – 2 (4%)
P = o.5
90 – Day All-Cause Mortality
N – 35 (18%)
N – 31 (16%)
P = 0.60
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